Literature DB >> 22541290

Neurological phenotypes for Down syndrome across the life span.

Ira T Lott1.   

Abstract

This chapter reviews the neurological phenotype of Down syndrome (DS) in early development, childhood, and aging. Neuroanatomic abnormalities in DS are manifested as aberrations in gross brain structure as well as characteristic microdysgenetic changes. As the result of these morphological abnormalities, brain circuitry is impaired. While an intellectual disability is ubiquitous in DS, there is a wide range of variation in cognitive performance and a growing understanding between aberrant brain circuitry and the cognitive phenotype. Hypotonia is most marked at birth, affecting gait and ligamentous laxity. Seizures are bimodal in presentation with infantile spasms common in infancy and generalized seizures associated with cognitive decline observed in later years. While all individuals have the characteristic neuropathology of Alzheimer's disease (AD) by age 40 years, the prevalence of dementia is not universal. The tendency to develop AD is related, in part, to several genes on chromosome 21 that are overexpressed in DS. Intraneuronal accumulation of β-amyloid appears to trigger a cascade of neurodegeneration resulting in the neuropathological and clinical manifestations of dementia. Functional brain imaging has elucidated the temporal sequence of amyloid deposition and glucose metabolic rate in the development of dementia in DS. Mitochondrial abnormalities contribute to oxidative stress which is part of AD pathogenesis in DS as well as AD in the general population. A variety of medical comorbidities threaten cognitive performance including sleep apnea, abnormalities in thyroid metabolism, and behavioral disturbances. Mouse models for DS are providing a platform for the formulation of clinical trials with intervention targeted to synaptic plasticity, brain biochemistry, and morphological brain alterations.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541290      PMCID: PMC3417824          DOI: 10.1016/B978-0-444-54299-1.00006-6

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  158 in total

Review 1.  Down syndrome and beta-amyloid deposition.

Authors:  Elizabeth Head; Ira T Lott
Journal:  Curr Opin Neurol       Date:  2004-04       Impact factor: 5.710

2.  Neuropsychological correlates of word identification in Down syndrome.

Authors:  Deborah J Fidler; David E Most; Mark M Guiberson
Journal:  Res Dev Disabil       Date:  2005 Sep-Oct

3.  Emotional competence in children with Down syndrome: negativity and regulation.

Authors:  Laudan B Jahromi; Amanda Gulsrud; Connie Kasari
Journal:  Am J Ment Retard       Date:  2008-01

Review 4.  Drug targets for cognitive enhancement in neuropsychiatric disorders.

Authors:  Tanya L Wallace; Theresa M Ballard; Bruno Pouzet; Wim J Riedel; Joseph G Wettstein
Journal:  Pharmacol Biochem Behav       Date:  2011-04-01       Impact factor: 3.533

Review 5.  Cognitive deficits and associated neurological complications in individuals with Down's syndrome.

Authors:  Ira T Lott; Mara Dierssen
Journal:  Lancet Neurol       Date:  2010-06       Impact factor: 44.182

6.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.

Authors:  D M Holtzman; D Santucci; J Kilbridge; J Chua-Couzens; D J Fontana; S E Daniels; R M Johnson; K Chen; Y Sun; E Carlson; E Alleva; C J Epstein; W C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

7.  Okadaic acid induces apoptosis in Down syndrome fibroblasts.

Authors:  G Dogliotti; E Galliera; E Dozio; E Vianello; R E Villa; F Licastro; I Barajon; M M Corsi
Journal:  Toxicol In Vitro       Date:  2009-12-13       Impact factor: 3.500

8.  Urinary uric acid and antioxidant capacity in children and adults with Down syndrome.

Authors:  Carlos Campos; Rodrigo Guzmán; Encarnación López-Fernández; Angela Casado
Journal:  Clin Biochem       Date:  2009-09-26       Impact factor: 3.281

9.  Daytime sleepiness and hyperactivity in children with suspected sleep-disordered breathing.

Authors:  Ma Cecilia S Melendres; Janita M Lutz; Eric D Rubin; Carole L Marcus
Journal:  Pediatrics       Date:  2004-09       Impact factor: 7.124

10.  Treated hypothyroidism, cognitive function, and depressed mood in old age: the Rancho Bernardo Study.

Authors:  Caroline K Kramer; Denise von Mühlen; Donna Kritz-Silverstein; Elizabeth Barrett-Connor
Journal:  Eur J Endocrinol       Date:  2009-09-15       Impact factor: 6.664

View more
  72 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 2.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

3.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

Review 4.  Emerging connections between cerebellar development, behaviour and complex brain disorders.

Authors:  Aaron Sathyanesan; Joy Zhou; Joseph Scafidi; Detlef H Heck; Roy V Sillitoe; Vittorio Gallo
Journal:  Nat Rev Neurosci       Date:  2019-05       Impact factor: 34.870

5.  Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain.

Authors:  J London; F K Ndiaye; L C Bui; B Souchet; F Daubigney; C Magnan; S Luquet; J Dairou; N Janel; C Rouch
Journal:  Mol Neurobiol       Date:  2018-09-20       Impact factor: 5.590

Review 6.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

7.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

8.  Frontal white matter integrity in adults with Down syndrome with and without dementia.

Authors:  David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2014-02-04       Impact factor: 4.673

9.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

Review 10.  Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease.

Authors:  Huntington Potter; Antoneta Granic; Julbert Caneus
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.